Glactone Pharma profiled in BioCentury


Glactone Pharma AB have been featured in an emerging company profile in BioCentury, the Bernstein report on biobusiness. In the article innovator Rebecka Hellsten commented on the recent publication in the Journal of Biological Chemistry and project manager Martin Johansson described Glactone Pharma’s unique strategy of inhibiting STAT3. The article can be viewed here (PDF).